E Skurikhin, N Ermakova, M Zhukova, E Pan, D Widera, L Sandrikina, L Kogai, O Pershina, A Pakhomova, V Yu Pan, N Kushlinskii, A Kubatiev, S Morozov, A Dygai
BACKGROUND: Metastatic disease is a major and difficult-to-treat complication of lung cancer. Considering insufficient effectiveness of existing therapies and taking into account the current problem of lung cancer chemoresistance, it is necessary to continue the development of new treatments. METHODS: Previously, we have demonstrated the antitumor effects of reprogrammed CD8+ T-cells (rCD8+ T-cells) from the spleen in mice with orthotopic lung carcinoma. Reprogramming was conducted by inhibiting the MAPK/ERK signalling pathway through MEKi and the immune checkpoint PD-1/PD-L1...
April 25, 2024: BMC Cancer